EcoDrugPlus

Leukotriene B4 Receptor 1-Like

Ensembl ID : ENSLBEG00000015827
Gene Symbol: LOC109999492
3 Cross references
157 Possible Orthologues:

Leukotriene B4 Receptor 1-Like

Ensembl ID : ENSLBEG00000015849
Gene Symbol: LOC109999475
3 Cross references
142 Possible Orthologues:

Lutropin-Choriogonadotropic Hormone Receptor-Like

Ensembl ID : ENSLBEG00000027081
Gene Symbol: LOC109993303
4 Cross references
200 Possible Orthologues:

Lysine Demethylase 1a

Ensembl ID : ENSLBEG00000000983
Gene Symbol: KDM1A
3 Cross references
212 Possible Orthologues:

Lysyl Oxidase Homolog 2a-Like

Ensembl ID : ENSLBEG00000015243
Gene Symbol: LOC109983894
3 Cross references
208 Possible Orthologues:

Lysyl Oxidase Homolog 2b-Like

Ensembl ID : ENSLBEG00000027152
Gene Symbol: LOC109993933
3 Cross references
213 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 1-Like

Ensembl ID : ENSLBEG00000027619
Gene Symbol: LOC109992605
3 Cross references
63 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 2-Like

Ensembl ID : ENSLBEG00000018170
Gene Symbol: LOC110000123
2 Cross references
204 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSLBEG00000011148
Gene Symbol: MIF
3 Cross references
229 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSLBEG00000018750
Gene Symbol: MST1R
3 Cross references
193 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSLBEG00000021142
Gene Symbol: LOC109980643
2 Cross references
188 Possible Orthologues:

Mast/stem Cell Growth Factor Receptor Kita-Like

Ensembl ID : ENSLBEG00000028818
Gene Symbol: LOC109992796
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).